More than one-third of a cohort of autistic toddlers no longer meet criteria for the condition at school age, according to a new study, but the findings may not generalize because the cohort is predominantly white and affluent.
After 10 years of work, Neurona may have the data to quiet its skeptics. But its ongoing clinical trial will be the ultimate test.
The new devices, which monitor neural activity from within blood vessels, show long-term stability in rats and could one day deliver electrical stimulation.
The New York State Psychiatric Institute in New York City is undergoing an audit and a change in leadership following a suicide that occurred during one of its clinical trials.
Contrary to conventional wisdom, most people with fragile X syndrome express the FMR1 gene — albeit improperly.
The discovery could help clinicians diagnose children who carry mutations in the gene, called SCN2A, and gauge their responses to potential therapies.
In this episode of “Synaptic,” Kasari talks about the need for inclusion in educating autistic children, what drew her into the autism research field, and growing up on the family farm.
Neuronal alterations outside the brain may help to explain a host of the condition’s characteristic traits, including sensory changes, gut problems and motor differences.
The changes may help explain the link between maternal infection and autism, though more research is needed.
Some conditions are too rare for conventional drug trials, leading some scientists to test bespoke treatments in single participants. Gleeson discusses the merits — and limitations — of these tiny trials.